INTRODUCTION
============

Much effort has been made over a long period of time to identify prognostic biomarkers in pancreatic cancer (PC) patients. Fortunately, a large body of literature has covered the survival of PC patients with abnormal microRNA (miRNA) expression \[[@r1]--[@r169]\]. Among all kinds of human cancers, PC has one of the worst prognoses, with a 5-year overall survival (OS) rate of lower than 5% \[[@r170]\]. Despite advances in clinical treatments and new surgical techniques, the survival rate of PC patients has been low for more than 30 years \[[@r171]\]. PC is highly aggressive; therefore, distant metastasis and tissue invasion may occur at early stages \[[@r172]\]. Since invasion and metastasis are the biggest obstacles to effective treatment of PC, it is imperative to explore the molecular biological mechanism leading to such invasive behavior to improve the survival time of patients.

miRNAs are small noncoding RNAs involved in gene regulation \[[@r173]\]. In cancers, a few upregulated miRNAs can serve as oncogenes (oncomiRs) \[[@r174]\], and downregulated miRNAs can serve as tumor suppressors \[[@r175]\]. Expression profiling data analyses have revealed signatures of diagnosis and prognosis that have been employed to stratify various tumor types \[[@r174], [@r176]\]. As a consequence, miRNAs have the potential to turn into clinical biomarkers for human tumors and into molecular therapeutic targets \[[@r177]\].

Despite comprehensive studies focused on illustrating the molecular biological mechanisms in PC, there are still challenges confronting the identification of minimally invasive and sensitive biomarkers of prognosis. Consequently, it is of vital significance to find prognostic signatures that can be conveniently and reliably applied in the clinical setting to improve the survival time of PC patients.

Increasing evidence indicates that miRNAs have the potential to act as PC prognostic biomarkers in clinical practice \[[@r1]--[@r169]\]. Regrettably, there has not been a meta-analysis to evaluate the relationship between dysregulated miRNA expression and survival in PC patients. In view of our previous work, meta-analyses of miRNA expression and cancer patients \[[@r178], [@r179]\], it is necessary to conduct the current work by searching the recently published literature about miRNAs as prognostic tools in PC tissue or blood.

RESULTS
=======

Meta-analysis
-------------

An overview of the HR with 95%CI obtained from the overall comprehensive analysis for all included miRNAs is shown in [Table 1](#t1){ref-type="table"}. Based on the logical order of the miRNA names, the forest plot, Begg's funnel plot, sensitivity analysis and funnel plot of the merged analysis adjusted with the trim and fill method are shown in [Figures 1](#f1){ref-type="fig"}--[7](#f7){ref-type="fig"}. The mean NOS score of the included studies was 7.0 (5.0-8.0), indicating that their quality was adequate ([Table 2](#t2){ref-type="table"}).

###### Summary about results of meta-analysis for miRNA expression in pancreatic cancer.

  ---------------- ------------ ----------------------- ------------------------ ---------------------- -------- ----------- ------------ ------------- -------------------------------------------- --------------------
  **miRNA**        **Sample**   **Survival analysis**   **Number of articles**   **Included studies**   **HR**   **95%CI**   **Figure**   **P value**   **Heterogeneity (Higgins I^2^ statistic)**   **Total patients**
  High miR-21      Blood        OS                      5                        4-8                    2.61     1.68-4.04   2            \<0.01        I^2^=33.8%, P=0.20                           326
  High miR-196a    Blood        OS                      2                        16,17                  1.61     0.50-5.23   2            0.43          I^2^=79.5%, P=0.03                           66
  High miR-451a    Blood        OS                      3                        7,8,23                 2.23     1.23-4.04   2            \<0.01        I^2^=2.1%, P=0.36                            137
  High miR-1290    Blood        OS                      2                        24,26                  1.43     1.04-1.95   2            0.03          I^2^=0.0%, P=0.76                            223
  High miR-10b     Tissue       OS                      4                        35-38                  1.73     1.09-2.76   3            0.02          I^2^=61.5%, P=0.03                           375
  High miR-17-5p   Tissue       OS                      3                        39-41                  1.91     1.30-2.80   3            \<0.01        I^2^=0.0%, P=0.96                            164
  High miR-21      Tissue       OS                      19                       5,43-60                1.90     1.61-2.25   3            \<0.01        I^2^=43.9%, P=0.02                           1947
  High miR-21      Tissue       OS^m^                   8                        5,45-48,50-52          2.43     1.89-3.13   4            \<0.01        I^2^=0.0%, P=0.73                            592
  High miR-21      Tissue       OS^Adjusted^                                                            1.58     1.32-1.89                \<0.01        I^2^=58.6%, P\<0.01                          
  High mIR-23a     Tissue       OS                      4                        50,53,61,62            2.18     1.52-3.13   8            \<0.01        I^2^=0.0%, P=0.51                            251
  Low miR-29c      Tissue       OS                      4                        33,46,69,70            1.39     1.08-1.79   8            0.01          I^2^=51.8%, P=0.10                           463
  Low miR-126      Tissue       OS                      3                        27,68,82               1.55     1.23-1.95   8            \<0.01        I^2^=0.0%, P=0.99                            455
  High miR-155     Tissue       OS                      3                        14,50,51               2.22     1.27-3.88   8            \<0.01        I^2^=0.0%, P=0.47                            211
  Low mIR-200c     Tissue       OS                      3                        109-111                1.40     0.51-3.79   8            0.51          I^2^=87.2%, P\<0.01                          258
  High miR-203     Tissue       OS                      4                        59,112-114             1.65     1.14-2.40   8            \<0.01        I^2^=83.6%, P\<0.01                          619
  Low miR-218      Tissue       OS                      3                        121-123                2.62     1.41-4.88   8            \<0.01        I^2^=57.5%, P=0.10                           248
  High miR-221     Tissue       OS                      4                        46,50,125,126          1.72     1.08-2.74   8            0.02          I^2^=4.9%, P=0.37                            187
  High miR-222     Tissue       OS                      3                        28,126,127             1.72     1.02-2.91   8            0.04          I^2^=36.8%, P=0.21                           322
  ---------------- ------------ ----------------------- ------------------------ ---------------------- -------- ----------- ------------ ------------- -------------------------------------------- --------------------

HR: hazard ratios; CI: confidence intervals; OS: overall survival; ^m^multivariate analysis; ^Adjusted^Adjusted with the trim and fill method.

###### Newcastle-Ottawa scale quality assessment results.

  ------------------------- ---------- --------------- --------------- ------------------- ------------- -----------
  **First author**          **Year**   **Reference**   **Selection**   **Comparability**   **Outcome**   **Total**
  Liu                       2012       \[[@r4]\]       ★★★             ★★                  ★★            7
  Wang                      2013       \[[@r5]\]       ★★★             ★★                  ★★            7
  Abue                      2015       \[[@r6]\]       ★★★             ★★                  ★★            7
  Goto                      2018       \[[@r7]\]       ★★★             ★★                  ★★            7
  Kawamura                  2019       \[[@r8]\]       ★★★             ★★                  ★★★           8
  Mikamori                  2017       \[[@r14]\]      ★★★             ★★                  ★★★           8
  Kong                      2010       \[[@r16]\]      ★★★             ★★                  ★★            7
  Yu                        2017       \[[@r17]\]      ★★★             ★★                  ★★            7
  Takahasi                  2018       \[[@r23]\]      ★★★             ★★                  ★★            7
  Li                        2013       \[[@r24]\]      ★★★             ★★                  ★★★           8
  Tavano                    2013       \[[@r26]\]      ★★★             ★★                  ★★            7
  Liao                      2018       \[[@r27]\]      ★★★             ★★                  ★★            7
  Schultz                   2012       \[[@r28]\]      ★★★             ★★                  ★★            7
  Wang                      2019       \[[@r33]\]      ★★              ★                   ★★★           6
  Nakata                    2011       \[[@r35]\]      ★★              ★                   ★★★           6
  Preis                     2011       \[[@r36]\]      ★★★             ★★                  ★★            7
  Nguyen                    2016       \[[@r37]\]      ★★★             ★★                  ★★            7
  Yang                      2017       \[[@r38]\]      ★★★             ★★                  ★★★           8
  Yu                        2010       \[[@r39]\]      ★★★             ★★                  ★★★           8
  Gu                        2016       \[[@r40]\]      ★★★             ★★                  ★★            7
  Zhu                       2018       \[[@r41]\]      ★★              ★                   ★★            5
  Dillhoff                  2008       \[[@r43]\]      ★★              ★                   ★★★           6
  Giovannetti               2010       \[[@r44]\]      ★★★             ★★                  ★★★           8
  Hwang                     2010       \[[@r45]\]      ★★★             ★★                  ★★★           8
  Jamieson                  2011       \[[@r46]\]      ★★★             ★★                  ★★            7
  Nagao                     2012       \[[@r47]\]      ★★★             ★★                  ★★            7
  Caponi                    2013       \[[@r48]\]      ★★★             ★★                  ★★★           8
  Kadera                    2013       \[[@r49]\]      ★★★             ★★                  ★★★           8
  Ma                        2013       \[[@r50]\]      ★★★             ★★                  ★★            7
  Papaconstantinou          2013       \[[@r51]\]      ★★★             ★★                  ★★★           8
  Donahue                   2014       \[[@r52]\]      ★★★             ★★                  ★★★           8
  Frampton                  2014       \[[@r53]\]      ★★★             ★★                  ★★            7
  Mitsuhashi                2015       \[[@r54]\]      ★★★             ★★                  ★★            7
  Vychytilova-Faltejskova   2015       \[[@r55]\]      ★★              ★                   ★★            5
  Morinaga                  2016       \[[@r56]\]      ★★★             ★★                  ★★★           8
  Benesova                  2018       \[[@r57]\]      ★★★             ★★                  ★★            7
  Xi                        2018       \[[@r58]\]      ★★              ★                   ★★★           6
  Zhang                     2018       \[[@r59]\]      ★★              ★                   ★★★           6
  Zhao                      2018       \[[@r60]\]      ★★★             ★★                  ★★★           8
  Diao                      2018       \[[@r61]\]      ★★              ★                   ★★            5
  Wu                        2018       \[[@r62]\]      ★★★             ★★                  ★★            7
  Liang                     2018       \[[@r68]\]      ★★              ★                   ★★★           6
  Jiang                     2015       \[[@r69]\]      ★★              ★                   ★★            5
  Zou                       2015       \[[@r70]\]      ★★★             ★★                  ★★            7
  Yu                        2018       \[[@r82]\]      ★★★             ★★                  ★★★           8
  Yu                        2010       \[[@r109]\]     ★★★             ★★                  ★★★           8
  Paik                      2015       \[[@r110]\]     ★★★             ★★                  ★★★           8
  Liu                       2016       \[[@r111]\]     ★★★             ★★                  ★★★           8
  Ikenaga                   2010       \[[@r112]\]     ★★★             ★★                  ★★★           8
  Shao                      2017       \[[@r113]\]     ★★              ★                   ★★★           6
  Shi                       2018       \[[@r114]\]     ★★              ★                   ★★★           6
  Li                        2013       \[[@r121]\]     ★★★             ★★                  ★★            7
  Zhu                       2014       \[[@r122]\]     ★★★             ★★                  ★★            7
  Li                        2015       \[[@r123]\]     ★★★             ★★                  ★★★           8
  Sarkar                    2013       \[[@r125]\]     ★★              ★                   ★★★           6
  Wang                      2016       \[[@r126]\]     ★★★             ★★                  ★★            7
  Lee                       2013       \[[@r127]\]     ★★★             ★★                  ★★            7
  ------------------------- ---------- --------------- --------------- ------------------- ------------- -----------

![**Forest plot about OS of PC patients with high miR-21, miR-196a, miR-451a or miR-1290 level in blood**](aging-12-103214-g001){#f1}

High miR-21, miR-451a and miR-1290 levels in the blood predict poor OS
----------------------------------------------------------------------

Five studies \[[@r4]--[@r8]\] analyzed the connections between high blood miR-21 levels and OS, indicating that PC patients with high blood miR-21 levels had significantly poorer OS than those with low levels (HR=2.61, 95%CI=1.68-4.04, P\<0.01, [Figure 1](#f1){ref-type="fig"}).

Two studies \[[@r16], [@r17]\] reported the relationship between high blood miR-196a levels and OS, but no significant associations were found between high blood miR-196a and OS (HR=1.61, 95%CI=0.50-5.23, P=0.43, [Figure 1](#f1){ref-type="fig"}).

Three studies \[[@r7], [@r8], [@r23]\] focused on the correlativity between high blood miR-451a levels and OS, indicating that PC patients with high miR-451a levels had significantly shorter OS than those with low levels (HR=2.23, 95%CI=1.23-4.04, P\<0.01, [Figure 1](#f1){ref-type="fig"}).

Two studies \[[@r24], [@r26]\] stressed the pertinence between high blood miR-1290 levels and OS, suggesting that PC patients with high miR-1290 levels had significantly worse OS than those with low levels (HR=1.43, 95%CI=1.04-1.95, P=0.03, [Figure 1](#f1){ref-type="fig"}).

High miR-10b, miR-17-5P, miR-21, miR-23a, miR-155, miR-203, miR-221, and miR-222 levels or low miR-29c, miR-126, and miR-218 levels in tissues predict poor OS
--------------------------------------------------------------------------------------------------------------------------------------------------------------

The details are shown in [Table 1](#t1){ref-type="table"} and [Figures 2](#f2){ref-type="fig"} and [7](#f7){ref-type="fig"}.

![**Forest plot about OS of PC patients with high miR-10b, miR-17-5P or miR-21 level in tissue.**](aging-12-103214-g002){#f2}

High miR-21 levels in tissues predict poor OS (multivariate analysis)
---------------------------------------------------------------------

The details are shown in [Table 1](#t1){ref-type="table"} and [Figure 3](#f3){ref-type="fig"}.

![**Forest plot about OS of PC patients with high miR-21 level in tissue (multivariate analysis).**](aging-12-103214-g003){#f3}

Publication bias
----------------

Begg's funnel plot was employed to estimate publication bias in the study of OS in PC patients with high tissue miR-21 levels ([Figure 4](#f4){ref-type="fig"}). The results showed that the P value was less than 0.01, indicating the presence of publication bias.

![**Begg's funnel plot about OS of PC patients with high miR-21 level in tissue.**](aging-12-103214-g004){#f4}

Sensitivity analysis
--------------------

Sensitivity analysis was used to estimate whether any single study had undue influence on the OS of PC patients with high tissue miR-21 levels ([Figure 5](#f5){ref-type="fig"}). The outcome showed that no single investigation significantly affected the pooled HR and 95%CI.

![**Sensitivity analysis about OS of PC patients with high miR-21 level in tissue.**](aging-12-103214-g005){#f5}

The trim and fill method
------------------------

As such ([Figure 4](#f4){ref-type="fig"}), the trim and fill method was conducted, and the pooled HR was recalculated with assumed lost studies to assess dissymmetry in the funnel plot ([Figure 6](#f6){ref-type="fig"}), manifesting no publication bias (P=0.80). The recalculated HR did not change significantly for OS (HR=1.58, 95%CI=1.32-1.89, P\<0.01).

![**Funnel plot about pooled analysis adjusted with trim and fill method of OS of PC patients with high miR-21 level in tissue. Circles: included studies; diamonds: presumed missing studies.**](aging-12-103214-g006){#f6}

![**Forest plot about OS of PC patients with high miR-23a, miR-155, miR-203, miR-221, miR-222 or low miR-29c, miR-126, miR-200c, miR-218 level in tissue.**](aging-12-103214-g007){#f7}

DISCUSSION
==========

Foremost findings
-----------------

The current meta-analysis included 57 English articles that incorporated 15 miRNAs and 5445 patients. As the most researched miRNA, PC patients with high blood or tissue miR-21 levels had significantly poorer OS than those with low levels. It also proved true among PC patients with high tissue miR-21 levels (multivariate analysis) and pooled analysis adjusted with the trim and fill method of OS, indicating that miR-21 is a stable and useful prognostic biomarker in PC. Moreover, a few other miRNAs had significant prognostic impact on PC, including blood miR-451a, and miR-1290 and tissue miR-10b, miR-17-5p, miR-29c, miR-126, miR-155, miR-203, miR-218, miR-221, and miR-222. Among these, blood miR-21, and miR-451a and tissue miR-23a, miR-155, and miR-218 were strong biomarkers of prognosis for PC.

Altered expression, potential targets and pathways for studied miRNAs
---------------------------------------------------------------------

In addition, an overview of the 15 miRNAs with dysregulated levels, covering the validated targets and pathways, is shown in [Table 3](#t3){ref-type="table"}. Most of the included miRNAs showed stable expression levels, higher or lower than the control groups except miR-200c. In brief, [Table 3](#t3){ref-type="table"} could support a better understanding of the molecular biological mechanisms of miRNAs in PC.

###### Summary of miRNAs with altered expression, their validated targets and pathways entered this study.

  ----------- -------------------------------------- ---------------- ----------------------- --------------------------------------------------------------------------------------------------
  **miRNA**   **Reference**                          **Expression**   **Potential target**    **Pathway**
  10b         \[[@r35]--[@r38]\]                     Up               None                    Cell invasion
  17-5p       \[[@r39]--[@r41]\]                     Up               PTEN,RBL2               Cell cycle, invasion and proliferation
  21          \[[@r4]--[@r8],[@r43]--[@r60]\]        Up               BTG2,FASL,PDCD4,SPRY2   Cell apopsotis, chemoresistance, cycle, proliferation, FASL/FAS, MAPK/ERK and PI3K/AKT signaling
  23a         \[[@r50], [@r53], [@r61], [@r62]\]     Up               ESRP1,FOXP2,NEDD4L      Cell invasion, epithelial-mesenchymal transition, migration and proliferation
  29c         \[[@r33], [@r46], [@r69], [@r70]\]     Down             MMP2                    Cell invasion, migration and Wnt signaling
  126         \[[@r27], [@r68], [@r82]\]             Down             None                    None
  155         \[[@r14], [@r50], [@r51]\]             Up               None                    None
  196a        \[[@r16],[@r17]\]                      Up               None                    None
  200c        \[[@r109]--[@r111]\]                   Unstable         None                    Cell invasion and proliferation
  203         \[[@r59], [@r112]--[@r114]\]           Up               None                    None
  218         \[[@r121]--[@r123]\]                   Down             UGT8,VOPP1              Cell proliferation
  221         \[[@r46], [@r50], [@r125], [@r126]\]   Up               None                    Cell migration and proliferation
  222         \[[@r28], [@r126], [@r127]\]           Up               NOSTRIN                 None
  451a        \[[@r7], [@r8], [@r23]\]               Up               None                    None
  1290        \[[@r24], [@r26]\]                     Up               None                    None
  ----------- -------------------------------------- ---------------- ----------------------- --------------------------------------------------------------------------------------------------

PTEN: phosphatase and tensin homolog; RBL2: RB transcriptional corepressor like 2; BTG2: BTG anti-proliferation factor 2; FASL: Fas ligand; PDCD4: programmed cell death 4; SPRY2: sprouty RTK signaling antagonist 2; ESRP1: epithelial splicing regulatory protein 1; FOXP2: forkhead box P2; NEDD4L: NEDD4 like E3 ubiquitin protein ligase; UGT8: UDP glycosyltransferase 8; VOPP1: VOPP1 WW domain binding protein; NOSTRIN: nitric oxide synthase trafficking; FAS: Fas cell surface death receptor; MAPK: mitogen-activated protein kinase; ERK: extracellular regulated protein kinases; PI3K: phosphoinositide-3-kinase; AKT: AKT serine/threonine kinase 1.

Superiorities of the meta-analysis
----------------------------------

The present work had two strengths : (1) we looked for and found out almost all studies with OS in PC patients with dysregulated miRNA levels. In addition, the recent miRNA expression pattern is shown in [Tables 4](#t4){ref-type="table"} and [5](#t5){ref-type="table"} that differentiates miRNA names and the sample types. (2) The majority of included articles had large sample sizes (≥30, all but 4 studies \[[@r6], [@r41], [@r121], [@r125]\]), intensifying and widening the applicability of the prognostic outcomes for PC patients.

###### Frequency of studies estimating prognostic value of blood miRNA expression in pancreatic cancer.

  ----------- ------- ------- --------- ------- ------- --------- ------- -------- --------- ------- -------
  **miR**     **N**   **R**   **miR**   **N**   **R**   **miR**   **N**   **R**    **miR**   **N**   **R**
  let-7b-5p   1       1       107       1       11      203       1       18       483-3p    1       6
  16-2-3p     1       2       124       1       12      205       1       19       486-3p    1       24
  19a-3p      1       1       125b-5p   1       13      210       1       17       602       1       2
  19b-3p      1       1       150       1       10      222       1       20       629       1       25
  21-5p       1       3       155       1       14      223-3p    1       1        877-5p    1       2
  21          5       4-8     182       1       15      301a-3p   1       21       890       1       2
  25-3p       1       1       191       1       7       373       1       22       1290      2       24,26
  33a         1       9       192-5p    1       1       375       1       3        3201      1       2
  34a         1       10      196a      2       16,17   451a      3       7,8,23   4525      1       8
  ----------- ------- ------- --------- ------- ------- --------- ------- -------- --------- ------- -------

Highlighted studies were included in the present meta-analysis; N: Number of studies estimating prognostic value; R: References.

###### Frequency of studies estimating prognostic value of tissue miRNA expression in pancreatic cancer.

  ---------- ------- ------------- --------- ------- ---------- --------- ------- --------------- --------- ------- --------- --------- ------- -------
  **miR**    **N**   **R**         **miR**   **N**   **R**      **miR**   **N**   **R**           **miR**   **N**   **R**     **miR**   **N**   **R**
  let-7a-3   1       27            92b-3p    1       75         155       3       14,50,51        301a-3p   1       129       509-5p    1       151
  let-7g\*   1       28            93        1       38         181c      1       100             301b      1       38        539       1       152
  let-7g     1       29            96-5p     1       76         182-5p    1       76              323-3p    1       130       545       1       153
  1          1       30            100       2       50,77      183       1       101             326       1       71        548an     1       154
  7-5p       1       31            101       1       78         191       1       102             328       1       68        590-5p    1       38
  9-5p       1       32            103       1       79         192       2       33,103          329       1       131       613       1       155
  9          1       33            107       1       80         195       1       104             337       1       132       615-5p    1       156
  10a-5p     1       34            124       1       81         196a-2    1       105             342-3p    2       53,133    661       1       157
  10b        4       35-38         125a-3p   1       29         196b      2       59,106          361-3p    1       134       663       1       158
  15b        1       38            125a      1       68         198       2       55,107          367       1       135       664a      1       68
  17-5p      3       39-41         125b      1       77         199a-3p   1       53              371-5p    1       136       664       1       159
  19a        1       42            126       3       27,68,82   200c-3p   1       108             374b-5p   1       137       675-5p    1       160
  21         19      5,43-60       130b      1       83         200c      3       109-111         375       1       50        675       1       28
  23a        4       50,53,61,62   132       2       33,84      203       4       59,112-114      376b      1       68        708-5p    1       161
  24-1       1       27            133a-1    1       27         204-5p    1       115             376c      1       68        744       1       162
  25-3p      1       63            133a      2       33,85      204       1       95              377       1       138       891b      1       163
  26a        1       64            135b-5p   2       86,87      205-5p    1       29              410-3p    1       139       940       1       164
  27a        1       53            135b      1       88         205       2       19,116          421       1       27        1181      1       165
  29a-5p     1       29            137       1       89         211       1       117             424       2       82,114    1246      1       166
  29a        1       65            139-5p    1       90         212-3p    1       29              429       1       140       1247      1       167
  29b-2-5p   1       66            139       1       91         212       2       28,118          448       1       141       1266      1       168
  29b-3p     1       67            140       1       33         214       1       30              450b-5p   1       28        1293      1       114
  29b        2       33,68         141       2       92,93      216b-5p   1       119             451       1       142       1301      1       68
  29c        4       33,46,69,70   142-3p    2       53,94      216b      1       120             454       1       68        3157      1       27
  30a        1       71            142-5p    1       95         217       1       50              483-3p    1       143       3613      1       68
  30b        1       72            143       1       50         218       3       121-123         491       1       33        3656      1       169
  30d        1       46            146a      1       28         219       1       71              494       3       144-146   4521      1       27
  30e        1       27            148a\*    1       28         221-3p    1       124             495       1       147       4709      1       27
  31         2       50,54         148a      1       50         221       4       46,50,125,126   497       1       148       5091      1       27
  34a-5p     2       29,73         148b      1       96         222       3       28,126,127      501-3p    1       149                         
  34a        1       46            150       1       97         223       1       128             501       1       27                          
  34b        1       74            153       2       98,99      224       2       46,71           506       1       150                         
  ---------- ------- ------------- --------- ------- ---------- --------- ------- --------------- --------- ------- --------- --------- ------- -------

Highlighted studies were included in the present meta-analysis; N: Number of studies estimating prognostic value; R: References.

Drawbacks
---------

The following drawbacks of the current meta-analysis should considered: (1) there were numerous variables, consisting of dissimilar sample types from PC patients at different stages, cutoffs, and miRNA detection methods, among which the differences in sample type and cutoffs were the main drawbacks; (2) we only selected English articles, perhaps excluding potential papers published in other languages about PC patients with miRNA expression levels and prognostic outcomes; (3) we only chose studies estimating OS, perhaps excluding potential investigations reporting prognosis with other survival results, such as disease-free and recurrence-free survival; (4) the prognostic impact of miRNA expression levels in pancreatic cancer should be adjusted for risk factors that have an important influence on pancreatic cancer prognosis, such as age, educational level, sex, smoking, obesity, heavy alcohol intake, underlying illnesses and family history of cancer, which indicates possible mutations. However, the searched papers may not all contain the very concerned information. Therefore, the impact of bias in predicting miRNAs involved in pancreatic cancer prognosis may occur due to the lack of adjustment for risk factors in a rigorous conclusion.

Insight for future clinical and experimental studies
----------------------------------------------------

Notably, this study was the first meta-analysis of the associations between abnormal miRNA levels and prognosis in PC patients. This study provides direction for further clinical and experimental study: (1) joint detection of various miRNA levels could be utilized by clinical workers and other health care providers, which might extremely expand the ability to assess the prognosis of PC patients such that immediate treatment might be supplied; (2) advances and trends regarding miRNA expression levels and the survival time of PC patients could be obviously acquired by the experimental researchers mentioned in [Tables 4](#t4){ref-type="table"} and [5](#t5){ref-type="table"}. In addition, miRNA molecular mechanisms could be obtained by assessing the data in [Table 3](#t3){ref-type="table"}; and (3) several contradictory outcomes concerning the prognostic value of miRNAs might be resolved on account of the present work.

CONCLUSIONS
===========

In summary, blood miR-21, miR-451a, miR-1290 and tissue miR-10b, miR-17-5p, miR-21, miR-23a, miR-29c, miR-126, miR-155, miR-203, miR-218, miR-221, miR-222 had significant prognostic value.

MATERIALS AND METHODS
=====================

Search strategy
---------------

Two independent authors (Fei Zhao and Chao Wei) performed the literature search from 4 online databases, PubMed, EMBASE, Web of Science and Cochrane Database of Systematic Reviews. Afterwards, Yue Zhang reassessed undetermined information. An extensive and comprehensive search was performed utilizing the keywords: 'microRNA', 'miRNA', 'miR', and 'pancreatic cancer', 'pancreatic carcinoma' and 'pancreatic adenocarcinoma'. After duplicates were eliminated, 875 reports remained. Accordingly, 671 articles were excluded by titles and abstracts. For the residual 204 studies, 35 full-text studies were removed. The details of the literature selection are shown in [Figure 8](#f8){ref-type="fig"}. The search deadline was June 1, 2019.

![**Flow diagram of literature search and selection.**](aging-12-103214-g008){#f8}

Inclusion criteria
------------------

The inclusion criteria were as follows: (1) articles on the correlation between miRNA expression level and survival time of PC patients; (2) inclusion of estimated OS outcomes; and (3) full-text in English.

Exclusion criteria
------------------

The exclusion criteria were as follows: (1) articles without original data (reviews, letters or laboratory studies); (2) nondichotomous miRNA level; and (3) frequency of studies evaluating OS of miRNA expression level equal or less than 2 in tissue. In addition, on the condition that more than one article was published on the same subjects, the most well-rounded paper was chosen for the present work. Likewise, if both univariate and multivariate analysis of OS were covered, the latter was chosen, as this type of analysis considers interferential factors.

Quality assessment
------------------

Fei Zhao and Chao Wei confirmed all qualified studies that analyzed the prognostic value of miRNAs in PC, and Yue Zhang reevaluated undetermined information. Quality assessment for each paper was performed employing the modified Newcastle--Ottawa Scale (NOS) \[[@r180]\]. NOS scores were calculated according to selection, comparability, and outcome. Articles with NOS scores ≥6 were considered high-quality articles \[[@r181]\].

Study selection
---------------

The flow chart with details of the study selection process is given in [Figure 8](#f8){ref-type="fig"}.

Study frequency
---------------

The frequency of studies estimating the OS of PC patients with and miRNA expressions of PC patients is presented in Tables 4 (blood) and 5 (tissue), and includes the miRNA names, the frequency of included miRNAs, and the reference number.

Study characteristics
---------------------

The fundamental particulars of the included literature are fully listed in [Table 6](#t6){ref-type="table"}. On the condition that the data were not offered in the article but just as Kaplan--Meier survival curves, the data were abstracted from the curves, and the generation of HR with 95% CI was next carried out employing the software Engauge Digitizer version 4.1.

###### Characteristics of included studies about pancreatic cancer.

  ----------- ------------------------------------------ ----------------- ------------ ------------ ----------- ------------- ------------ ----------------------- ------------ -------------- -------------- ------------
  **miRNA**   **Study**                                  **Country**       **Sample**   **Number**   **Stage**   **Cut-off**   **Method**   **Follow-up (month)**   **Result**   **HR (L/H)**   **HR (H/L)**   **95%CI**
  21          Liu, 2012 \[[@r4]\]                        China             Serum        38           I-IV        Median        qRT-PCR      24                      OS^u^                       3.26           1.47-7.23
  21          Wang, 2013 \[[@r5]\]                       China             Serum        177          III-IV      Median        qRT-PCR      30                      OS^m^                       1.71           1.15-2.54
  21          Abue, 2015 \[[@r6]\]                       Japan             Plasma       24           I-IV        850           qRT-PCR      \>20                    OS^u^                       5.99           1.95-18.40
  21          Goto, 2018 \[[@r7]\]                       Japan             Serum        32           I-IV        Median        qRT-PCR      \>40                    OS^u^                       2.57           0.90-7.35
  21          Kawamura, 2019 \[[@r8]\]                   Japan             Plasma       55           I-II        Mean          qRT-PCR      60                      OS^m^                       3.10           1.19-9.10
  196a        Kong, 2010 \[[@r16]\]                      China             Serum        35           I-IV        -5.22         qRT-PCR      \>16                    OS^u^                       3.37           1.14-9.97
  196a        Yu, 2017 \[[@r17]\]                        China             Plasma       31           None        Median        qRT-PCR      15                      OS^m^                       0.99           0.92-1.06
  451a        Goto, 2018 \[[@r7]\]                       Japan             Serum        32           I-IV        Median        qRT-PCR      \>40                    OS^u^                       1.45           0.63-3.31
  451a        Takahasi, 2018 \[[@r23]\]                  Japan             Plasma       50           I-II        Median        qRT-PCR      54                      OS^m^                       3.20           1.07-11.94
  451a        Kawamura, 2019 \[[@r8]\]                   Japan             Plasma       55           I-II        Mean          qRT-PCR      60                      OS^m^                       3.60           1.13-11.31
  1290        Li, 2013 \[[@r24]\]                        USA               Serum        56           I-III       Median        qRT-PCR      \>80                    OS^u^                       1.63           0.66-3.98
  1290        Tavano, 2013 \[[@r26]\]                    Italy             Plasma       167          I-IV        ROC           ddPCR        \>40                    OS^u^                       1.40           1.00-1.96
  10b         Nakata, 2011 \[[@r35]\]                    Japan             FFPE         115          None        None          qRT-PCR      101                     OS^u^                       2.19           1.37-3.50
  10b         Preis, 2011 \[[@r36]\]                     Lebanon           FFPE         95           I-IV        5000          ISH          36                      OS^u^                       3.59           1.73-7.43
  10b         Nguyen, 2016 \[[@r37]\]                    USA               Frozen       55           I-II        1.5 fold      qRT-PCR      34.25                   OS^u^                       1.12           0.54-2.32
  10b         Yang, 2017 \[[@r38]\]                      Germany I         Frozen       69           I-IV        None          qRT-PCR      \>60                    OS^u^                       1.99           1.07-3.73
                                                         Germany II        Frozen       41           I-IV        None          qRT-PCR      \>60                    OS^u^                       0.81           0.39-1.67
  17-5p       Yu, 2010 \[[@r39]\]                        Japan             FFPE         80           I-IV        5.69          qRT-PCR      100                     OS^u^                       1.85           1.08-3.15
  17-5p       Gu, 2016 \[[@r40]\]                        China             Tissue       58           I-IV        None          qRT-PCR      \>50                    OS^u^                       1.89           0.98-3.64
  17-5p       Zhu, 2018 \[[@r41]\]                       China             Tissue       26           None        None          qRT-PCR      \>50                    OS^u^                       2.18           0.77-6.17
  21          Dillhoff, 2008 \[[@r43]\]                  USA               FFPE         80           None        Median        ISH          \>60                    OS^u^                       4.23           2.17-8.25
  21          Giovannetti, 2010 \[[@r44]\]               Italy             Frozen       59           I-IV        Median        qRT-PCR      60.5                    OS^u^                       2.31           1.30-4.10
  21          Hwang, 2010 \[[@r45]\]                     Korea and Italy   Tissue       97           II-IV       Median        qRT-PCR      \>60                    OS^m^                       3.16           1.67-6.02
  21          Jamieson, 2011 \[[@r46]\]                  UK                Frozen       48           None        Median        qRT-PCR      \>50                    OS^m^                       3.22           1.21-8.58
  21          Nagao, 2012 \[[@r47]\]                     Japan             FFPE         65           None        Mean          qRT-PCR      \>40                    OS^m^                       2.12           1.07-4.20
  21          Caponi, 2013 \[[@r48]\]                    Italy and UK      FFPE         57           None        Median        qRT-PCR      117.3                   OS^m^                       3.28           1.52-7.05
  21          Kadera, 2013 \[[@r49]\]                    USA               Tissue       145          I-II,IV     Median        ISH          100                     OS^u^                       1.06           0.70-1.60
  21          Ma, 2013 \[[@r50]\]                        China             Frozen       78           I-IV        2 fold        qRT-PCR      \>25                    OS^m^                       2.60           1.15-5.87
  21          Papaconstantinou, 2013 \[[@r51]\]          Greece            FFPE         88           None        Mean          qRT-PCR      \>60                    OS^m^                       3.93           1.25-12.35
  21          Wang, 2013 \[[@r5]\]                       China             Tissue       65           III-IV      Median        qRT-PCR      60                      OS^m^                       2.24           1.14-4.37
  21          Donahue, 2014 \[[@r52]\]                   USA I             FFPE         94           I-IV        Median        ISH          72                      OS^m^                       1.70           1.03-2.82
                                                         USA II            FFPE         87           I-IV        Median        ISH          72                      OS^u^                       0.94           0.59-1.49
  21          Frampton, 2014 \[[@r53]\]                  UK                Frozen       91           IIA,IIB     Median        qRT-PCR      \>48                    OS^u^                       1.85           1.08-3.18
  21          Mitsuhashi, 2015 \[[@r54]\]                Japan             FFPE         283          I-IV        75%           qRT-PCR      48                      OS^u^                       1.60           1.07-2.39
  21          Vychytilova-Faltejskova, 2015 \[[@r55]\]   Czech             FFPE         74           None        27.15         qRT-PCR      \>40                    OS^u^                       1.76           1.08-2.86
  21          Morinaga, 2016 \[[@r56]\]                  Japan             FFPE         39           None        Median        ISH          114.1                   OS^u^                       1.80           0.90-3.60
  21          Benesova, 2018 \[[@r57]\]                  Czech             FFPE         91           II-IV       Median        qRT-PCR      18                      OS^u^                       1.60           1.02-2.50
  21          Xi, 2018 \[[@r58]\]                        TCGA              Tissue       169          I-IV        Median        Downloaded   60                      OS^u^                       1.47           1.00-2.16
  21          Zhang, 2018 \[[@r59]\]                     GEO               Tissue       174          I-IV        Median        Downloaded   \>80                    OS^u^                       1.89           1.37-2.62
  21          Zhao, 2018 \[[@r60]\]                      Japan             Tissue       63           0-IV        None          qRT-PCR      \>60                    OS^u^                       2.99           1.25-7.14
  23a         Ma, 2013 \[[@r50]\]                        China             Frozen       78           I-IV        2 fold        qRT-PCR      \>25                    OS^u^                       1.64           0.71-3.79
  23a         Frampton, 2014 \[[@r53]\]                  UK                Frozen       91           IIA,IIB     Median        qRT-PCR      \>48                    OS^u^                       1.87           1.07-3.16
  23a         Diao, 2018 \[[@r61]\]                      China             Frozen       30           None        Median        qRT-PCR      25                      OS^u^                       2.55           1.10-5.92
  23a         Wu, 2018 \[[@r62]\]                        China             Tissue       52           None        3.5           qRT-PCR      \>50                    OS^u^                       3.64           1.56-8.47
  29c         Jamieson, 2011 \[[@r46]\]                  UK                Frozen       48           None        Median        qRT-PCR      \>50                    OS^m^        1.89                          0.68-5.26
  29c         Jiang, 2015 \[[@r69]\]                     TCGA              Frozen       132          I-IV        None          Downloaded   \>50                    OS^u^        1.59                          1.15-2.18
  29c         Zou, 2015 \[[@r70]\]                       China             FFPE         105          I-IV        Median        qRT-PCR      30                      OS^m^        1.14                          1.00-1.29
  29c         Wang, 2019 \[[@r33]\]                      GEO               Tissue       178          I-IV        None          Downloaded   \>80                    OS^u^        1.67                          1.05-2.63
  126         Liang, 2018 \[[@r68]\]                     TCGA              FFPE         175          I-IV        Median        Downloaded   \>83.3                  OS^m^        1.58                          1.04-2.39
  126         Liao, 2018 \[[@r27]\]                      TCGA              Tissue       112          I-II        None          Downloaded   \>40                    OS^u^        1.51                          0.98-2.32
  126         Yu, 2018 \[[@r82]\]                        TCGA              Tissue       168          I-II        Median        Downloaded   72.4                    OS^m^        1.55                          1.07-2.24
  155         Ma, 2013 \[[@r50]\]                        China             Frozen       78           I-IV        2 fold        qRT-PCR      \>25                    OS^m^                       1.37           0.52-3.58
  155         Papaconstantinou, 2013 \[[@r51]\]          Greece            FFPE         88           None        Mean          qRT-PCR      \>60                    OS^m^                       3.14           1.09-9.09
  155         Mikamori, 2017 \[[@r14]\]                  Japan             Tissue       45           I-II        Mean          qRT-PCR      \>72                    OS^m^                       2.63           1.07-6.46
  200c        Yu, 2010 \[[@r109]\]                       Japan             FFPE         99           I-IV        0.64          qRT-PCR      101                     OS^m^        2.25                          1.10-4.60
  200c        Paik, 2015 \[[@r110]\]                     Korea             FFPE         84           IB-III      0.65          qRT-PCR      140                     OS^m^        0.56                          0.34-0.93-
  200c        Liu, 2016 \[[@r111]\]                      China             Tissue       75           I-IV        Mean          qRT-PCR      60                      OS^m^        2.31                          1.73-6.38
  203         Ikenaga, 2010 \[[@r112]\]                  Japan             FFPE         107          I-IV        0.054         qRT-PCR      98                      OS^m^                       1.21           0.72-2.07
  203         Shao, 2017 \[[@r113]\]                     TCGA              Tissue       161          I-IV        None          Downloaded   \>80                    OS^u^                       2.18           1.31-2.49
  203         Shi, 2018 \[[@r114]\]                      TCGA              Tissue       177          None        Median        Downloaded   \>72                    OS^u^                       1.24           1.10-1.39
  203         Zhang, 2018 \[[@r59]\]                     GEO               Tissue       174          I-IV        Median        Downloaded   \>80                    OS^u^                       2.27           1.57-3.27
  218         Li, 2013 \[[@r121]\]                       China             FFPE         28           None        1.5 fold      qRT-PCR      \>20                    OS^u^        1.86                          0.80-4.35
  218         Zhu, 2014 \[[@r122]\]                      China             Frozen       113          I-IV        Mean          qRT-PCR      \>50                    OS^m^        2.12                          1.51-2.50
  218         Li, 2015 \[[@r123]\]                       China             Frozen       107          I-IV        Median        qRT-PCR      60                      OS^m^        7.24                          2.01-18.28
  221         Jamieson, 2011 \[[@r46]\]                  UK                Frozen       48           None        Median        qRT-PCR      \>50                    OS^m^                       0.92           0.34-2.54
  221         Ma, 2013 \[[@r50]\]                        China             Frozen       78           I-IV        2 fold        qRT-PCR      \>25                    OS^m^                       2.00           0.87-4.62
  221         Sarkar, 2013 \[[@r125]\]                   USA               FFPE         24           None        None          qRT-PCR      \>83.3                  OS^u^                       1.36           0.52-3.51
  221         Wang, 2016 \[[@r126]\]                     Germany           Frozen       37           I-II        66.7%         qRT-PCR      \>40                    OS^u^                       2.85           1.20-6.77
  222         Schultz, 2012 \[[@r28]\]                   Denmark           FFPE         225          I-II        Median        qRT-PCR      24                      OS^m^                       1.39           1.06-1.84
  222         Lee, 2013 \[[@r127]\]                      China             Frozen       60           I-IV        Median        qRT-PCR      15                      OS^m^                       5.16           1.16-22.91
  222         Wang, 2016 \[[@r126]\]                     Germany           Frozen       37           I-II        None          qRT-PCR      \>40                    OS^u^                       1.86           0.79-4.37
  ----------- ------------------------------------------ ----------------- ------------ ------------ ----------- ------------- ------------ ----------------------- ------------ -------------- -------------- ------------

HR (L/H): hazard ratios of low expression versus high expression of miRNAs; HR (H/L): hazard ratios of high expression versus low expression of miRNAs; CI: confidence intervals; TCGA: The Cancer Genome Atlas; GEO: Gene Expression Omnibus; FFPE: formalin-fixed paraffin-embedded; qRT-PCR: quantitative real-time polymerase chain reaction; ddPCR: droplet digital polymerase chain reaction; ISH: in-situ hybridization; OS: overall survival; ^u^Univariate analysis; ^m^Multivariate analysis.

Statistical analysis
--------------------

All analyses were carried out employing Stata version 13.0 (StataCorp, College Station, TX, USA). OS was the primary and unique guideline for the prognosis of PC patients with miRNAs. The HR was regarded as significant at the P \<0.05 level in case of the 95% CI not including the value 1. Furthermore, a single miRNA was considered a strong candidate if its HR was over 2. Most analyses used random-effects models other than fixed-effects models because of the dissimilarity of sample types from PC patients at dissimilar stages, cutoffs, and miRNA methods in single studies. Begg's funnel plot was used to estimate publication bias. A two-tailed P value less than 0.05 was regarded as significant. If publication bias occurred, the trim and fill method was conducted. The sensitivity analysis was employed to assess how sensitive the entire effect size was to remove the impact of single investigations. If the point estimation was outside of the 95% CI of the entire effect value after it was excluded from the entire analysis, a single study was deemed to have undue influence.
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